Gatifloxacinのヒト髄液中移行の検討

書誌事項

タイトル別名
  • Pharmacokinetic Study of Gatifloxacin
  • Penetration of Gatifloxacin into Cerebrospinal Fluid

この論文をさがす

抄録

We investigated the penetration of gatifloxacin (GFLX), a new quinolone derivative, into human cerebrospinal fluid (CSF). Patients who needed to undergo urological surgery under lumbar spinal anesthesia, and who had no central nervous system diseases which interfered with the study, were given GFLX, and then CSF and serum were collected by dura puncture about 3 hours after dosing. Concentrations of GFLX in CSF and serum were determined by the HPLC method.<BR>Mean CSF and serum concentrations of the drug after a single oral dose of 200 mg GFLX were 0.21±0.16 and 1.67±0.43 μg/mL, respectively. The mean ratio of CSF/serum concentration was 0.11±0.07.<BR>In the multiple-dose group, to whom 200 mg GFLX was given orally twice a day for 3 days, the mean CSF concentration of GFLX was 0.82 ±0.31/μg/mL, and the mean serum concentration was 2.47±0.96μg/mL. The mean ratio of CSF/serum concentrations was 0.35±0.10, about 3 times greater than that in the single-dose group.<BR>The ratio of CSF/serum concentration of GFLX in both the single-and multiple-dose groups was similar to those of other quinolones.<BR>No clinically significant adverse reactions and no abnormal laboratory test findings were observed.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (23)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ